Onderneming Phio Pharmaceuticals Corp.
Aandelen
PHIO
US71880W4024
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,682 USD | -3,40% | +6,58% | -10,26% |
Vakgebied
Aantal werknemers: 9
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19-06-12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-17 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 10-11-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19-06-12 |
Director/Board Member | 73 | 02-05-22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18-04-13 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 07-06-17 |
Robert Ferrara
BRD | Director/Board Member | 73 | 01-10-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 4 591 700 | 4 564 638 ( 99,41 %) | 0 | 99,41 % |
Bedrijfsgegevens
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508 767 3861
http://www.phiopharma.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-10,26% | 3,24 mln. | |
+1,51% | 42,59 mld. | |
+8,57% | 40,65 mld. | |
+49,22% | 40,57 mld. | |
-12,36% | 26,77 mld. | |
+8,92% | 24,81 mld. | |
-25,13% | 18,17 mld. | |
+29,17% | 12,05 mld. | |
-3,12% | 11,7 mld. | |
+6,35% | 11,1 mld. |
- Beurs
- Aandelen
- Koers PHIO
- Onderneming Phio Pharmaceuticals Corp.